• Blog
  • California Consumer Privacy Act (CCPA)
  • Cart
  • Checkout
  • Contact
  • DMCA
  • Home
  • My account
  • Privacy Policy
  • Shop
Tuesday, October 7, 2025
  • Login
Buyer's Insight
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact
No Result
View All Result
Buyer's Insight
No Result
View All Result

Biocon Arm receives the temporary approval of the USFDA for the tablets used to treat stomach aches

Michael Johnson by Michael Johnson
October 7, 2025
in Business & Economy
Reading Time: 1 min read
0
0
SHARES
0
VIEWS
Biocon Ltd. actions Attend volatile movements on Tuesday, October 7, after its entirely subsidiary belonging to provisional approval of the Food and Drug Administration of the United States (USFDA) for the new abbreviated medication request (ANDA) for the Rifaximin tablets, 550 mg.

Biocon Pharma Ltd., Biocon’s Arm, has teamed up with Carnegie Pharmaceuticals for the drug.

Tablets are a rifamycin antibacterial indicated to reduce the risk of manifest hepatic epippleathy and to treat irritable colon syndrome with adults, according to Biocon.

In an earlier interaction with CNBC-TV18, biocon management stressed that it is well placed to stimulate the creation of long-term value during exercise 26 and beyond, with strong progress in all its companies and an increased capacity of American acquisitions by generic Syngene and Biocon.

Biocon shares had opened more on Tuesday, but are currently in the event of the summits, exchanging 0.3% more to $ 348.65. The action decreased by 4% in the last month and is down more than 5% on an annual basis.

Source link

Post Views: 0
Tags: achesapprovalArmBioconreceivesstomachTabletstemporarytreatUSFDA
Previous Post

Do buyers care who designs fashion collections?

Next Post

Techcrunch Disrupt 2025 The exhibition tables are sold quickly and time is exhausted

Related Posts

Business & Economy

What then happens in France after the resignation of Lecornu?

October 7, 2025
Business & Economy

Delhivery shares increase for the third day while Macquarie projects 17% increase, Kotak improves

October 7, 2025
Business & Economy

Trump’s tax changes to your charity donations: what

October 7, 2025
Business & Economy

October 15 Technological offers Prime Day that I would do as a technical publisher

October 7, 2025
Business & Economy

Nestlé wins the Battle of the Maggi brand while the court supports the settlement with the utensil company

October 7, 2025
Business & Economy

Instagram will attribute the best creators with a gold ring. But no money

October 7, 2025
Next Post

Techcrunch Disrupt 2025 The exhibition tables are sold quickly and time is exhausted

Zoma News Pulse

  • Home
  • California Consumer Privacy Act (CCPA)
  • Contact
  • DMCA
  • Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Top Stories
  • Local News
    • Politics
    • Business & Economy
    • Entertainment
    • Sports
  • Health
  • Lifestyle
  • Science & Environment
  • Technology
  • Review Radar
    • Weight Loss Products Reviews
    • Forex Trading
    • Shop
  • Contact